Literature DB >> 29118907

NOVA1 acts as an oncogene in osteosarcoma.

Chengzhen Li1,2, Ying He2, Haijing Ma2, Seongho Han1.   

Abstract

Osteosarcoma is one of the most common bone tumors in young patients. NOVA1 (neuro-oncological ventral antigen 1) is a neuron-specific RNA binding-protein and belongs to the Nova family. Previous studies showed that NOVA1 played crucial roles in the development of several tumors. The objective of our study was to study the role of NOVA1 in the osteosarcoma. In our study, we showed that NOVA1 expression was upregulated in osteosarcoma cell lines and tissues. The expression of NOVA1 was upregulated in 22 (22/30; 73%) osteosarcoma cases compared to that in the adjacent tissues. Overexpression of NOVA1 promoted osteosarcoma cell viability, colony formation and invasion. Furthermore, knockdown of NOVA1 suppressed osteosarcoma cell viability, colony formation and invasion. These data suggested that NOVA1 acted as an oncogene in the development of osteosarcoma.

Entities:  

Keywords:  NOVA1; Osteosarcoma; RNA binding-proteins; oncogene

Year:  2017        PMID: 29118907      PMCID: PMC5666054     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  31 in total

1.  MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN.

Authors:  Lei Shen; Xiao-Dong Chen; Yao-Hui Zhang
Journal:  Tumour Biol       Date:  2013-10-15

2.  A large-scale functional screen identifies Nova1 and Ncoa3 as regulators of neuronal miRNA function.

Authors:  Peter H Störchel; Juliane Thümmler; Gabriele Siegel; Ayla Aksoy-Aksel; Federico Zampa; Simon Sumer; Gerhard Schratt
Journal:  EMBO J       Date:  2015-06-23       Impact factor: 11.598

3.  miR-181c associates with tumor relapse of high grade osteosarcoma.

Authors:  Federica Mori; Andrea Sacconi; Valeria Canu; Federica Ganci; Mariangela Novello; Vincenzo Anelli; Renato Covello; Virginia Ferraresi; Paola Muti; Roberto Biagini; Giovanni Blandino; Sabrina Strano
Journal:  Oncotarget       Date:  2015-06-10

4.  Low miR-34a and miR-192 are associated with unfavorable prognosis in patients suffering from osteosarcoma.

Authors:  Yuan Wang; Lian-Shun Jia; Wen Yuan; Zhao Wu; Hai-Bo Wang; Tao Xu; Jing-Chuan Sun; Ke-Fu Cheng; Jian-Gang Shi
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

5.  miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2).

Authors:  Xiao-hui Sun; Xiao-lin Geng; Jun Zhang; Chao Zhang
Journal:  Tumour Biol       Date:  2014-11-18

6.  MicroRNA-497 suppresses osteosarcoma tumor growth in vitro and in vivo.

Authors:  Liang Ge; Baisong Zheng; Minghe Li; Liang Niu; Zhihong Li
Journal:  Oncol Lett       Date:  2016-01-29       Impact factor: 2.967

7.  MiR-100 Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion and Enhances Chemosensitivity by Targeting IGFIR.

Authors:  Yang Liu; Shu-Tao Zhu; Xiao Wang; Jun Deng; Wei-Hua Li; Peng Zhang; Bing-Shan Liu
Journal:  Technol Cancer Res Treat       Date:  2015-08-25

8.  miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells.

Authors:  Zaidoun Salah; Rand Arafeh; Vadim Maximov; Marco Galasso; Saleh Khawaled; Samah Abou-Sharieha; Stefano Volinia; Kevin B Jones; Carlo M Croce; Rami I Aqeilan
Journal:  Oncotarget       Date:  2015-03-10

9.  MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells.

Authors:  Ziqiang Zhu; Jinshan Tang; Jianqiang Wang; Gang Duan; Lei Zhou; Xiaoqing Zhou
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

10.  p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.

Authors:  Chiara Novello; Laura Pazzaglia; Amalia Conti; Irene Quattrini; Serena Pollino; Paola Perego; Piero Picci; Maria Serena Benassi
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

View more
  3 in total

1.  LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis.

Authors:  Yongxian Cao; Feng Zhang; Haotian Wang; Chunhua Bi; Jinpeng Cui; Fenghai Liu; Huazheng Pan
Journal:  Mol Cell Biochem       Date:  2020-09-23       Impact factor: 3.396

2.  Landscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification.

Authors:  Hong-Xin Su; Gang Yang; Fei Su; Chen-Xiao Hu; Tao Zhang; Jun-Tao Ran; Quan-Lin Guan
Journal:  J Immunol Res       Date:  2022-07-04       Impact factor: 4.493

3.  NOVA1 expression is associated with clinicopathological characteristics and prognosis in patients with small cell lung cancer.

Authors:  Meixuan Liu; Shuangshuang Deng; Tianyu Xiao; Jinli Gao
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.